A number of hemophilia B gene therapy products are at a more advanced stage of clinical development than for hemophilia A largely due to the lower complexity and size of the Factor IX (FIX) gene compared to that for FVIII; developing gene therapy techniques for the more prevalent hemophilia A form of the disease has been a considerable challenge [55-57]. This evidence concerns the gene F9 and hemophilia B.